Biomimetic Nanotechnology for Cancer Immunotherapy: State of the Art and Future Perspective Publisher Pubmed

Summary: Biomimetic nanoparticles target tumors precisely and reduce autoimmunity, aiding resistance-proof cancer therapy. #CancerImmunotherapy #BiomimeticNPs

Sarkar Lotfabadi A^{1, 2} ; Abadi B^{3, 4} ; Rezaei N^{2, 5, 6}
Source: International Journal of Pharmaceutics Published:2024

Abstract

Cancer continues to be a significant worldwide cause of mortality. This underscores the urgent need for novel strategies to complement and overcome the limitations of conventional therapies, such as imprecise targeting and drug resistance. Cancer Immunotherapy utilizes the body's immune system to target malignant cells, reducing harm to healthy tissue. Nevertheless, the efficacy of immunotherapy exhibits variation across individuals and has the potential to induce autoimmune responses. Biomimetic nanoparticles (bNPs) have transformative potential in cancer immunotherapy, promising improved accurate targeting, immune system activation, and resistance mechanisms, while also reducing the occurrence of systemic autoimmune side effects. This integration offers opportunities for personalized medicine and better therapeutic outcomes. Despite considerable potential, bNPs face barriers like insufficient targeting, restricted biological stability, and interactions within the tumor microenvironment. The resolution of these concerns is crucial in order to expedite the integration of bNPs from the research setting into clinical therapeutic uses. In addition, optimizing manufacturing processes and reducing bNP-related costs are essential for practical implementation. The present research introduces comprehensive classifications of bNPs as well as recent achievements in their application in cancer immunotherapies, emphasizing the need to address barriers for swift clinical integration. © 2024 Elsevier B.V.